We are live on ! Find out more
GALT icon

Galectin Therapeutics
GALT

50 hedge funds and large institutions have $4.85M invested in Galectin Therapeutics in 2016 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 10 increasing their positions, 14 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,181% more call options, than puts

Call options by funds: $730K | Put options by funds: $57K

14% less funds holding

Funds holding: 58 → 50 (-8)

17% less capital invested

Capital invested by funds: $5.88M → $4.85M (-$1.02M)

29% less repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 14

86% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 7

Holders
50
Holders Change
-8
Holders Change %
-13.79%
% of All Funds
1.33%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
10
Reduced
14
Closed
7
Calls
$730K
Puts
$57K
Net Calls
+$673K
Net Calls Change
-$73K

Top Buyers

Rank Fund Capital Flow
1
AIG
American International Group
New York
+$107K
2
DADC
D.A. Davidson & Co
Montana
+$67K
3
SGAM
Smith Group Asset Management
Texas
+$11K
4
BFM
Boothbay Fund Management
New York
+$8.3K
5
Commonwealth Equity Services
Commonwealth Equity Services
Massachusetts
+$4.54K

Top Sellers

Rank Fund Capital Flow
1
BCCM
Blue Clay Capital Management
Minnesota
-$122K
2
ARTA
A.R.T. Advisors
New York
-$53K
3
SIP
Stoneridge Investment Partners
Pennsylvania
-$46K
4
SIM
Spark Investment Management
New York
-$39K
5
BTS
BB&T Securities
Virginia
-$38K
Name Holding Trade Value Shares
Change 		Change in
Stake
SM
1
Sabby Management
Florida
$1.53M -$18.6K -13,850 -1%
Vanguard Group
2
Vanguard Group
Pennsylvania
$864K +$2.64K +1,968 +0.3%
DADC
3
D.A. Davidson & Co
Montana
$601K +$67K +49,909 +13%
AIG
4
American International Group
New York
$500K +$107K +79,500 +29%
Neuberger Berman Group
5
Neuberger Berman Group
New York
$132K – – –
US Bancorp
6
US Bancorp
Minnesota
$130K – – –
CS
7
Credit Suisse
Switzerland
$88K -$1.86K -1,389 -2%
BCA
8
Benchmark Capital Advisors
New York
$85K – – –
BFA
9
BlackRock Fund Advisors
California
$84K -$5.62K -4,182 -7%
GWM
10
Geneos Wealth Management
Colorado
$73K +$68.2K +50,812 New
BIT
11
BlackRock Institutional Trust
California
$60K – – –
Northern Trust
12
Northern Trust
Illinois
$56K -$5.36K -3,995 -9%
FIM
13
Freedom Investment Management
Connecticut
$54K -$11.2K -8,345 -18%
SGAM
14
Smith Group Asset Management
Texas
$49K +$11K +8,180 +31%
Commonwealth Equity Services
15
Commonwealth Equity Services
Massachusetts
$47K +$4.54K +3,385 +11%
CCB
16
Cutter & Co Brokerage
Missouri
$45K – – –
NPF
17
Norris Perne & French
Michigan
$44K – – –
CL
18
Croft-Leominster
Maryland
$42K – – –
Bank of New York Mellon
19
Bank of New York Mellon
New York
$35K – – –
California Public Employees Retirement System
20
California Public Employees Retirement System
California
$34K – – –
Millennium Management
21
Millennium Management
New York
$29K +$2.43K +1,807 +10%
BFM
22
Boothbay Fund Management
New York
$27K +$8.3K +6,180 +49%
SWP
23
Stratos Wealth Partners
Ohio
$26K – – –
Goldman Sachs
24
Goldman Sachs
New York
$23K -$10.3K -7,664 -32%
RG
25
Rathbones Group
United Kingdom
$23K – – –
1
2 3

GALT Hedge Fund Activity: Q1 2016 in Review

50 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q1 2016, worth a combined $4.85M — down 17% from $5.88M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of GALT and 1 opened new positions — a net loss of 6 holders — while 14 trimmed existing stakes and 10 added.

The largest buyer was American International Group, adding an estimated $107K. The largest seller was Blue Clay Capital Management, exiting entirely with an estimated $122K sold.

  • 50 institutional investors held Galectin Therapeutics (GALT) as of Q1 2016, down from 58 in Q4 2015.
  • Funds reported $4.85M of Galectin Therapeutics stock for Q1 2016, down 17% quarter-over-quarter.
  • 1 fund opened new Galectin Therapeutics positions in Q1 2016 and 7 closed out, a net change of -6 holders.
  • The largest Galectin Therapeutics buyer in Q1 2016 was American International Group, an estimated $107K added.
  • The largest Galectin Therapeutics seller in Q1 2016 was Blue Clay Capital Management, an estimated $122K sold.

Based on aggregated 13F filings for Q1 2016.